Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted after Desensitization

Transplantation

Volumn 99, Issue 7, 2015, Pages 1423-1430

  Vo, Ashley A ^a   Sinha, Aditi ^b   Haas, Mark ^a   Choi, Jua ^a   Mirocha, James ^a   Kahwaji, Joseph ^a   Peng, Alice ^a   Villicana, Rafael ^a   Jordan, Stanley C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; ALLOANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADVERSE EFFECTS; BLOOD; DRUG EFFECTS; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMORAL IMMUNITY; IMMUNOLOGY; KAPLAN MEIER METHOD; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; TIME FACTORS; TREATMENT OUTCOME;

EID: 84940722141     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000525     Document Type: Article

References (36)

1. Evans RW, Manninen DL, Garrison LP, et al. The quality of life of patients with end-stage renal disease. N Engl JMed. 1985;312:553.
2. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270:1339.
3. Organ Procurement and Transplantation Network. Scientific registry of transplant recipients. (accessed April 7, 2014, at http://optn.transplant. hrsa.gov).
4. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242.
5. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation. 2003;76:631.
6. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIg): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6:459.
7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH Ig02 trial. J Am Soc Nephrol. 2004;15:3256.
8. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6:346.
9. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887.
10. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation. 200886:820.
11. Cecka JM, Kucheryavaya AY, Reinsmoen NL, et al. Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant. 2011;11:719.
12. Lai CH, Cao K, Ong G, et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation. 2011;92:48.
13. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013;381:313.
14. Gloor JF, Cosio D, Lager J, et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant. 2008;8:1367.
15. Loupy A, Hill G, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8:348.
16. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6:922.
17. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med. 2011;365:318.
18. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14:255.
19. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398.
20. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713.
21. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272.
22. Lefaucheur C, Loupy A, Zeevi A. Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med. 2014;370:85.
23. Zachary AA, Lucas DP, Montgomery RA, et al. Rituximab prevents an anamnestic response in patients with cryptic sensitization to HLA. Transplantation. 2013;95:701.
24. Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant. 2012;12:469.
25. Lynch RJ, Silva IA, Chen BJ, et al. Cryptic B cell response to renal transplantation. Am J Transplant. 2013;13:1713.
26. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and costeffectiveness of desensitization using IVIg and rituximab. Transplantation. 2013;95:852.
27. Jordan SC, Reinsmoen N, Peng A, et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol. 2010; 25:2035.
28. Kim M, Martin ST, Townsend KR, et al. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014;34:733.
29. Vo AA, Choi J, Cisneros K, et al. Benefits of rituxmab combined with intravenous immunoglobulin for desensitization of renal transplant recipients. Transplantation. 2014;98:312.
30. Bentall A1, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant. 2013;13:76.
31. Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. 2014;14:1573.
32. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405.
33. Kerman R, Gebel H, Bray R, et al. HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Am J Transplant. 2002;2.
34. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89:1095.
35. Vo AA, Wechsler EA, Wang J, et al. Analysis of subcutaneous (Sq) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIg and rituximab. Am J Transplant. 2008;8:144.
36. Vo AA, Toyoda M, Peng A, et al. "Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIg." Am J Transplant. 2006;6:2384.